Table 91Summary of study characteristics for acamprosate versus placebo

Acamprosate versus placebo
Total number of trials (total number of participants)19 RCTs (N = 4629)
Study ID
DiagnosisDSM or ICD diagnosis of alcohol dependence
Baseline severityUnits consumed per week
Mean: 145.15
Range: 90 to 314.37
Mean dosage1998 mg per day
Length of treatmentRange: 8 weeks to 52 weeks
Length of follow-up
1.

Up to 12 months

2–3.

Not reported

4.

Up to 12 months

5.

Not reported

6.

Up to 12 months

7–11.

Not reported

12.

Up to 12 months and up to 18 months

13–14.

Not reported

15.

Up to 12 months

16.

Not reported

17.

Up to 12 months

18.

Not reported

19.

Up to 12 months and up to 24 months

Setting
1–2.

Outpatient

3.

Not reported

4–7.

Outpatient

8–9.

Inpatient/outpatient

10–12.

Outpatient

13.

Not reported

14–18.

Outpatient

19.

Inpatient/outpatient

Treatment goal
1–6.

Not reported

7–8.

Abstinence

9–14.

Not reported

15.

Abstinence

16–19.

Not reported

From: 7, PHARMACOLOGICAL INTERVENTIONS

Cover of Alcohol-Use Disorders
Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence.
NICE Clinical Guidelines, No. 115.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2011.
Copyright © 2011, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.